(Q37278239)

English

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

scientific article published on 20 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial (English)

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

0 references

type 2 diabetes

0 references

0 references

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Hans-Ulrich Häring

1

object named as

Hans-Ulrich Häring

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

author name string

Ludwig Merker

2

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Elke Seewaldt-Becker

3

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Marc Weimer

4

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Thomas Meinicke

5

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Hans J Woerle

6

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Uli C Broedl

7

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

EMPA-REG METSU Trial Investigators

8

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

language of work or name

0 references

publication date

20 August 2013

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

36

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

11

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

3396-3404

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

copyright license

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

1 September 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Standards of medical care in diabetes--2012

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Glucose handling by the kidney

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Renal glucose reabsorption inhibitors to treat diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Fate of the beta-cell in the pathophysiology of type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Weight change in diabetes and glycemic and blood pressure control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

6 September 2017

Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

26 June 2018

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 September 2018

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 September 2018

Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 September 2018

Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 September 2018

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 September 2018

Sulphonyurea as a cause of severe hypoglycaemia in the community.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 September 2018

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 September 2018

Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 September 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 December 2018

Uric Acid Level as a Risk Factor for Cardiovascular and All-Cause Mortality in Middle-aged Men

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3816918

3 December 2018

Uric acid and cardiovascular risk

1 reference

https://pubmed.ncbi.nlm.nih.gov/23963895

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan

1 reference

https://pubmed.ncbi.nlm.nih.gov/23963895

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Blood pressure and risk of cardiovascular diseases in type 2 diabetes: further findings from the Swedish National Diabetes Register (NDR-BP II)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23963895

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23963895

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/23963895

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2337/DC12-2673

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37278239&oldid=2097008511"